Table 2.

Clinical questions formulated and prioritized

Questions determined by the panel

1. Should older adults with newly diagnosed AML who are candidates for antileukemic therapy receive antileukemic therapy instead of best supportive care only?

2. Should older adults with newly diagnosed AML considered candidates for antileukemic therapy receive intensive antileukemic therapy vs less-intensive antileukemic therapy?

3. Should older adults with newly diagnosed AML who achieve remission after at least 1 cycle of intensive antileukemic therapy receive postremission therapy vs no additional therapy?

4. Should older adults with AML considered appropriate for antileukemic therapy but not for intensive antileukemic therapy receive gemtuzumab ozogamicin, low-dose cytarabine, azacitidine, 5-d decitabine, or 10-d decitabine as monotherapy or in combination?

5. Should older adults with AML who received less-intensive antileukemic therapy and who achieved a response continue therapy indefinitely until progression/toxicity or be given therapy for a finite number of cycles?

6. Should older adults with AML who are no longer receiving antileukemic therapy (including those receiving end-of-life or hospice care) receive RBC transfusions, platelet transfusions, or both, vs no transfusions?